PUMA BIOTECHNOLOGY, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
PUMA BIOTECHNOLOGY, INC. (PBYI) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 4.00 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-06
- PUMA BIOTECHNOLOGY, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-30 was 4.00M shares, a 38.48% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 3.87M shares, a 43.47% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 5.29B shares, a 21.21% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 6.51M shares, a 99.92% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 5.73B shares, a 10.22% decline from fiscal 2024.
- PUMA BIOTECHNOLOGY, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 6.38B shares, a 7.88% decline from fiscal 2023.
- PUMA BIOTECHNOLOGY, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 6.93B shares, a 1.81% increase from fiscal 2022.
- PUMA BIOTECHNOLOGY, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 6.81B shares, a 16.08% decline from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | 4.00M shares 10-Q · filed 2026-08-06 | 3.95M shares 10-Q · filed 2026-08-06 | |||||
| 2026-03-31 | 3.87M shares 10-Q · filed 2026-05-07 | ||||||
| 2025-12-31 | 5.73B shares 10-K · filed 2026-02-26 | ||||||
| 2025-09-30 | 5.29B shares 10-Q · filed 2025-11-06 | 6.19B shares 10-Q · filed 2025-11-06 | |||||
| 2025-06-30 | 6.51M shares 10-Q · filed 2026-08-06 | 6.51B shares 10-Q · filed 2025-08-07 | 6.63M shares 10-Q · filed 2026-08-06 | 6.63B shares 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | 6.85M shares 10-Q · filed 2026-05-07 | 6.85B shares 10-Q · filed 2025-05-08 | |||||
| 2024-12-31 | 6.38B shares 10-K · filed 2026-02-26 | ||||||
| 2024-09-30 | 6.72B shares 10-Q · filed 2025-11-06 | 6.72B shares 10-Q · filed 2025-11-06 | |||||
| 2024-06-30 | 7.76B shares 10-Q · filed 2025-08-07 | 7.76B shares 10-Q · filed 2025-08-07 | |||||
| 2024-03-31 | 7.94B shares 10-Q · filed 2025-05-08 | ||||||
| 2023-12-31 | 6.93B shares 10-K · filed 2025-02-27 | ||||||
| 2023-09-30 | 7.41B shares 10-Q · filed 2024-11-07 | 7.41M shares 10-Q · filed 2023-11-02 | 7.44B shares 10-Q · filed 2024-11-07 | 7.44M shares 10-Q · filed 2023-11-02 | |||
| 2023-06-30 | 7.99B shares 10-Q · filed 2024-08-01 | 7.99M shares 10-Q · filed 2023-08-03 | 7.08B shares 10-Q · filed 2024-08-01 | 7.08M shares 10-Q · filed 2023-08-03 | |||
| 2023-03-31 | 7.26B shares 10-Q · filed 2024-05-02 | ||||||
| 2022-12-31 | 6.81B shares 10-K · filed 2024-02-29 | ||||||
| 2022-09-30 | 7.93M shares 10-Q · filed 2023-11-02 | 7.93B shares 10-Q · filed 2022-11-03 | 8.69M shares 10-Q · filed 2023-11-02 | 8.69B shares 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | 7.84M shares 10-Q · filed 2023-08-03 | 7.84B shares 10-Q · filed 2022-08-04 | 8.05M shares 10-Q · filed 2023-08-03 | 8.05B shares 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | 8.73B shares 10-Q · filed 2023-05-04 | ||||||
| 2021-12-31 | 8.11B shares 10-K · filed 2024-02-29 | ||||||
| 2021-09-30 | 8.77B shares 10-Q · filed 2022-11-03 | 8.77B shares 10-Q · filed 2022-11-03 | |||||
| 2021-06-30 | 9.43B shares 10-Q · filed 2022-08-04 | 8.05B shares 10-Q · filed 2022-08-04 | |||||
| 2021-03-31 | 8.82B shares 10-Q · filed 2022-05-05 | ||||||
| 2020-12-31 | 8.98B shares 10-K · filed 2023-03-02 | ||||||
| 2020-09-30 | 9.53B shares 10-Q · filed 2021-11-04 | ||||||
| 2020-06-30 | 8.34B shares 10-Q · filed 2021-08-05 | 9.61B shares 10-Q · filed 2021-08-05 | |||||
| 2019-12-31 | 9.15B shares 10-K · filed 2022-03-03 | ||||||
| 2018-03-31 | 9.89M shares 10-Q · filed 2018-05-10 | ||||||
| 2017-03-31 | 9.55M shares 10-Q · filed 2018-05-10 | ||||||
| 2016-12-31 | 9.33M shares 10-K · filed 2019-03-01 | ||||||
| 2015-12-31 | 7.67M shares 10-K · filed 2018-03-09 | ||||||
| 2014-12-31 | 6.11M shares 10-K · filed 2017-03-01 | ||||||
| 2013-12-31 | 2.60M shares 10-K · filed 2016-02-29 | ||||||
| 2013-03-31 | 1.15M shares 10-Q · filed 2013-05-09 | ||||||
| 2012-12-31 | 4.02M shares 10-K · filed 2015-03-02 | ||||||
| 2012-09-30 | 1.42M shares 10-Q · filed 2013-11-12 | 1.42M shares 10-Q · filed 2013-11-12 | |||||
| 2012-06-30 | 1.39M shares 10-Q · filed 2013-08-06 | 1.39M shares 10-Q · filed 2013-08-06 | |||||
| 2011-12-31 | 670.00K shares 10-K · filed 2014-03-03 | ||||||
| 2010-12-31 | 0.00 shares 10-K · filed 2013-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |